First-line treatment with/without extended (maintenance) treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
Maintenance after first-line therapy: Treatment to prevent relapse after complete response to therapy
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Overall Survival (months)
The length of time where half the patients in the study are still alive
First-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| Angiogenesis Inhibitors: VEGF | NCT00262847; GOG-218 | III | Bevacizumab, Carboplatin, Paclitaxel Prescribing Information | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218) | Improved PFS, but no OS difference with addition of bevacizumab to carboplatin+paclitaxel; potential benefit for patients with stage IV disease CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac: All: Stage IV patients: pub 2019 |
| Angiogenesis Inhibitors: VEGF | NCT00483782; ICON7 | III | Bevacizumab, Carboplatin, Paclitaxel | ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer | Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac: All: pub 2011; 2015 |
| Angiogenesis Inhibitors: VEGF | NCT00951496; GOG-252 | III | Bevacizumab, Carboplatin, Cisplatin, Paclitaxel | A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Compared to the IV reference arm, PFS was not significantly increased with either IP regimen IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint: PFS: 24.9 vs 27.4 vs 26.2 months pub 2019 |
| Drugs in Clinical Development | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT02470585; VELIA | III | Carboplatin, Paclitaxel, Veliparib | A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Veliparib added to chemotherapy and continued as maintenance significantly extends PFS in all newly diagnosed patients, but shows most benefit in BRCA MUT patients CarboPt+Pac+Vel w/Vel maint vs CarboPt+Pac+Vel vs CarboPt+Pac: All patients: pub 2019 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT03326193; OVARIO | II | Bevacizumab, Carboplatin, Niraparib, Paclitaxel | Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab | Niraparib + bevacizumab maintenance treatment does not appear to cause cumulative toxicities and shows promising PFS PFS (6 months): 89.5% abs Mar 2020 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT00989651; GOG-9923 | I | Bevacizumab, Carboplatin, Cisplatin, Paclitaxel, Veliparib | A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Patients receiving IP cisplatin + IV/IP paclitaxel show promising PFS and OS when compared to patients receiving IV carboplatin+paclitaxel, however differences may be reflective of selection bias toward patients enrolled on the IP chemotherapy arm IV vs weekly IV vs IP (all w/ Vel cont): PFS: 24.5 vs 23.5 vs 43.2 months pub 2020, abs Mar 2020 |
| Immunotherapy: Checkpoint Inhibitors/PD-1 | NCT02766582 | II | Carboplatin, Paclitaxel, Pembrolizumab | Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer | Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising 28 patients abs Mar 2020 |
Maintenance after first-line therapy: Treatment to prevent relapse after complete response to therapy
For more detailed information, please click on the clinical trial ID number.
| Drug Class | Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|---|
| Standard of Care Targeted Drugs | |||||
| DNA Damage Repair Pathway Inhibitors: PARP | NCT01844986; SOLO-1 | III | Olaparib Prescribing Information | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy (SOLO-1) | Considerably improved PFS for BRCA MUT patients with olaparib maintenance treatment Ola maint vs Placebo: PFS: 56.0 vs 13.8 months* pub 2018, abs Sep 2020 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT02477644; PAOLA-1 | III | Bevacizumab, Carboplatin, Olaparib, Paclitaxel Prescribing Information | Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment | Dual maintenance therapy with olaparib and bevacizumab significantly improves PFS and PFS2 compared with bevacizumab maintenance alone for BRCA MUT and HRD+ patients Ola vs Placebo: All patients: abs Oct 2019, abs Sep 2020 |
| DNA Damage Repair Pathway Inhibitors: PARP | NCT02655016; PRIMA | III | Niraparib Prescribing Information | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Considerably improved PFS for all patients that received niraparib maintenance treatment Nir maint vs Placebo: All patients: pub 2019 |
| Drugs in NCCN Guidelines | |||||
| Hormonal Therapy: Aromatase | Retrospective Study: Hormonal Maintenance in LGSC | II | Anastrozole, Letrozole, Tamoxifen | Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation (OBS) in Low Grade Serous OC patients HMT vs OBS: PFS: 64.9 vs 26.4 months pub 2017 |
| Drugs in Clinical Development | |||||
| Chemotherapy | NCT00003120; GOG-178 | III | Paclitaxel | Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (GOG-178) | Improved PFS with 12 cycles of paclitaxel, no OS difference 12 cycles Pac vs 3 cycles Pac: PFS: 28 vs 21 months* pub 2003; 2009 |
| Chemotherapy | NCT00108745 | III | Paclitaxel, Paclitaxel Poliglumex | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | Improved PFS with paclitaxel poliglumex or paclitaxel maintenance treatment, but no OS difference Pac Poliglu vs Pac vs Placebo: PFS: 16.3 vs 18.9 vs 13.4 months* abs Mar 2017 |
| Angiogenesis Inhibitors: Multi-targeted RTK | NCT00866697; AGO-OVAR16 | III | Pazopanib | A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Improved PFS, but no OS benefit with pazopanib maintenance Paz vs Placebo: PFS: 17.9 vs 12.3 months* pub 2020 |
| Hormonal Therapy: Aromatase | Letrozole University Hospital Basel | Single-site | Letrozole | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients | Promising activity with minimal toxicity of letrozole maintenance in ER-positive patients Let vs Placebo: All patients: Patients w/o residual disease: Patients w/ residual disease: pub 2018 |
| Immunotherapy: Vaccine/TGFbeta | NCT01309230 | II | Gemogenovatucel-T | Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer | FANG vaccine shows encouraging anti-tumor activity and increased RFS with remarkable safety FANG vs Placebo: RFS (from time of procurement, mean/median): pub 2016 |
| Immunotherapy: Vaccine/TGFbeta | NCT02346747 | II | Gemogenovatucel-T | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy | Vigil immunotherapy as maintenance after first-line therapy in stage III–IV ovarian cancer is well tolerated and shows clinical benefit, particularly for BRCA WT patients 91 patients BRCA WT patients: abs Sep 2020 |